19-Hydroxytestosterone → 17beta,19-Dihydroxy-4-methyl-4-androsten-3-one

HRID 371850

Reaktionsgleichung

Reaktionsgleichung von HRID 371850
[OH:1][C@H:2]1[CH2:7][CH2:6][C@H:5]2[C@H:8]3[C@H:19]([CH2:20][CH2:21][C@:3]12[CH3:4])[C@:16]1([CH2:17][OH:18])[C:11](=[CH:12][C:13](=[O:22])[CH2:14][CH2:15]1)[CH2:10][CH2:9]3.[OH:23][CH2:24][C@@:25]12[C@@H:42]3[C@H:33]([C@H:34]4[C@@:38]([CH2:40][CH2:41]3)([CH3:39])[C:37](=[O:43])[CH2:36][CH2:35]4)[CH2:32][CH2:31][C:30]1=[CH:29][C:28](=[O:44])[CH2:27][C@@H:26]2[CH3:45].O[C@H:47]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@]1(CO)C(=CC(=O)CC1)C[C@H]3C>>[OH:1][C@H:2]1[CH2:7][CH2:6][C@H:5]2[C@H:8]3[C@H:19]([CH2:20][CH2:21][C@:3]12[CH3:4])[C@:16]1([CH2:17][OH:18])[C:11](=[C:12]([CH3:24])[C:13](=[O:22])[CH2:14][CH2:15]1)[CH2:10][CH2:9]3.[OH:23][CH2:24][C@@:25]12[C@@H:42]3[C@H:33]([C@H:34]4[C@@:38]([CH2:40][CH2:41]3)([CH3:39])[C:37](=[O:43])[CH2:36][CH2:35]4)[CH2:32][CH2:31][C:30]1=[C:29]([CH3:47])[C:28](=[O:44])[CH2:27][C@@H:26]2[CH3:45]

Komponenten

5

Edukt 3

HCID 15096819-HydroxytestosteroneHCID 7058400819-Hydroxy1alpha-methyl-4-androstene-3,17-dioneHCID 7058499517beta,19-Dihydroxy-7alpha-methyl-4-androstene-3-one

Produkt 2

HCID 5364116017beta,19-Dihydroxy-4-methyl-4-androsten-3-oneHCID 7058545619-Hydroxy-1alpha,4-dimethyl-4-androstene-3,17-dione

Versuchsvorschrift

Following essentially the same procedure and substituting 17β, 19-dihydroxy-4-androsten-3-one, 19-hydroxy-1α-methyl-4-androstene-3,17-dione and 17β,19-dihydroxy-7α-methyl-4-androstene-3-one for the 17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one above results in the preparation of 17β,19-dihydroxy-4-methyl-4-androsten-3-one, 19-hydroxy-1α,4-dimethyl-4-androstene-3,17-dione, and 17β,19-dihydroxy-4,7α-methyl-4-androsten-3-one, respectively.

Quellen und Nachweise

ORD-Eintrag
ord-d58bfc5e82ae41a3829b987158d635d0
Quelldatensatz
uspto-grants-1978_05
Patentnummer
US04087524

Verknüpfte Notizen

Wird geladen…